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Abstract 
Global insights into cellular organization and function require comprehensive 
understanding of interactome networks. Similar to how a reference genome sequence 
revolutionized human genetics, a reference map of the human interactome network is 
critical to fully understand genotype-phenotype relationships. Here we present the first 
human “all-by-all” binary reference interactome map, or “HuRI”. With ~53,000 high-
quality protein-protein interactions (PPIs), HuRI is approximately four times larger than 
the information curated from small-scale studies available in the literature. Integrating 
HuRI with genome, transcriptome and proteome data enables the study of cellular 
function within essentially any physiological or pathological cellular context. We 
demonstrate the use of HuRI in identifying specific subcellular roles of PPIs and protein 
function modulation via splicing during brain development. Inferred tissue-specific 
networks reveal general principles for the formation of cellular context-specific functions 
and elucidate potential molecular mechanisms underlying tissue-specific phenotypes of 
Mendelian diseases. HuRI thus represents an unprecedented, systematic reference 
linking genomic variation to phenotypic outcomes.  
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The reference human genome sequence has enabled systematic study of genetic1 and 
expression2 variability at the organism1, tissue2, cell type3 and single cell level4. Despite 
advances in sequencing genomes, transcriptomes and proteomes, we still understand little of 
the cellular mechanisms that mediate phenotypic and tissue or cell type variability. A 
mechanistic understanding of cellular function and organization emerges from studying how 
genes and their products, primarily proteins, interact with each other, forming a dynamic 
interactome that drives biological function. Analogous to the reference human genome 
sequence5,6, a reference map of the human protein interactome, generated systematically and 
comprehensively, would provide an unprecedented scaffold for the unbiased proteome-wide 
study of biological mechanisms, generally and within specific cellular contexts. Almost 20 years 
after the publication of a first draft of the reference human genome sequence5,6, a reference 
protein interactome map is yet to be reported. 
Proteins are biochemically more complex than DNA, the interactome is much more dynamic 
than the genome, and the search space for interactions requires testing all-by-all pairwise 
combinations, making interactome mapping extremely challenging. Approaches to human 
proteome-wide protein-protein interaction (PPI) mapping either aim to identify protein complex 
assemblies using mass spectrometry7–9 or direct PPIs using binary screening methods such as 
yeast two-hybrid (Y2H) followed by empirical validation using orthogonal assays10–12. In contrast 
to protein complex mapping, binary interactome mapping is based on interrogating pairs of 
proteins for interaction independently from any particular endogenous cellular context, thereby 
generating relatively unbiased systematic PPI datasets. For example, our most recent human 
protein interactome map (HI-II-14) described ~14,000 PPIs involving 4,000 proteins from 
screening ~40% of the genome-by-genome search space10 and in striking contrast to literature-
curated and protein complex interactome maps, HI-II-14 uniformly covered the proteome, free of 
study and expression bias. 
To increase interactome coverage and generate a first human reference interactome map, 
we have expanded the ORFeome collection to encompass ~90% of the protein-coding genome 
and screened this search space a total of nine times with a panel of assays using an enhanced 
screening platform. The resulting human binary PPI map doubles HI-II-14's coverage of the 
proteome and quadruples its interactome coverage. Integrating this PPI network with genome, 
transcriptome and proteome resources, we infer cellular context-specific views of the protein 
interactome, which are predictive of cellular context-specific gene function, at the level of 
individual subcellular compartments, cell types and tissues, across developmental stages and in 
disease (Fig. 1a). With its comprehensive view of the protein interactome, the resulting network 
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enables biological discovery across any cellular context, thus representing the first reference 
map of the human protein interactome. 
 
Generation and biophysical characterization of HI-III-19 
Our previously published human protein interactome map, HI-II-1410, covered less than half of 
the possible search space. To generate a more complete map, we established human 
ORFeome v9.1. This expanded ORFeome covers 17,408 protein-coding genes, on par with the 
number of genes found to be expressed in three comprehensive individual transcriptome 
sequencing studies2,3,13 (Fig. 1b) and includes 94% of the genes with robust evidence of 
expression in all three (Fig. 1c, Supplementary Table 1). The search space formed by 
hORFeome v9.1 (Space III), encompassing over 150 million binary combinations, more than 
doubles the space screened to generate HI-II-14 and represents the most comprehensive 
search space to be systematically screened for human PPIs. 
Limitations in PPI assay sensitivity can be overcome by employing different PPI assays14 or 
different versions of the same PPI assay15,16. To maximize sensitivity while maintaining high-
throughput screening capabilities, we employed three Y2H assay versions (Fig. 1d), which, 
when benchmarked against a gold standard positive and random reference set (PRSv1 and 
RRSv1)17, showed good sensitivity and low false positive rates while detecting complementary 
sets of PPIs (Extended Data Fig. 1a, b, Supplementary Table 2). We further assessed Y2H 
assay version quality, complementarity and screening behavior on a test space of ~2,000 by 
~2,000 human genes10. After verification by pairwise Y2H retesting and sequence confirmation, 
PPIs from each version were evaluated using MAPPIT18, an orthogonal assay. For each Y2H 
assay version, the recovery rate of PPIs was comparable or exceeded that of a set of PPIs from 
the literature with ≥ 2 pieces of experimental evidence, of which at least one comes from a 
binary assay type (Lit-BM)10 (Extended Data Fig. 1c, Supplementary Table 3). The Y2H assay 
versions were complementary, in that performing three screens with each version doubled the 
number of PPIs and proteins detected relative to performing the equivalent number of screens 
using a single assay version (Extended Data Fig. 1d, Supplementary Table 4). 
To construct the reference interactome, we performed nine screens of Space III, three with 
each Y2H assay version, followed by pairwise testing in quadruplicate, sequence confirmation, 
and validation using two orthogonal assays, MAPPIT18 and GPCA19. Screen PPIs were 
recovered at rates that were similar or superior to Lit-BM over a large range of score thresholds 
(Fig. 1e, Extended Data Fig. 1e-g, Supplementary Table 5), confirming the high quality of the 
interactome dataset. Each additional screen identified novel PPIs and proteins, with the largest 
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gains obtained by switching assay versions (Fig. 1f, g, Extended Data Fig. 1d), highlighting the 
importance of performing multiple screens and using several assay versions. The dataset, 
versioned HI-III-19 (Human Interactome obtained from screening Space III, published in 2019), 
contains 52,569 verified PPIs involving 8,275 proteins (Supplementary Table 6). Given its 
systematic nature, completeness and scale, we consider HI-III-19 to be the first draft of the 
Human Reference Interactome (HuRI).  
To assess whether assay complementarity can partially stem from different steric constraints 
in the protein fusions, we integrated HuRI with protein structure data20 and observed that the 
dataset is depleted for PPIs where the interaction interface is a short spatial distance (< 20Å) 
from the protein terminus fused to the AD domain (Extended Data Fig. 2a, b, Supplementary 
Table 7). These results provide the first systematic investigation into the impact of protein tags 
on PPI detection. 
Molecular mechanisms can be more readily inferred from direct PPIs, yet, the fraction of 
direct versus indirect PPIs reported in various human protein interactome maps is unknown. 
Using three-dimensional structural information from protein complexes with at least three 
subunits20,21, we show that the vast majority of PPIs in HuRI (90%) correspond to direct 
biophysical contacts, significantly higher than in Lit-BM (81%, P = 0.019, two-sided Fisher’s 
exact test, n = 121 (HuRI), 410 (Lit-BM)) or in protein complex interactome maps (less than 
50%, P < 0.001 for all, two-sided Fisher’s exact test) (Fig. 1h, Supplementary Table 8), 
demonstrating that HuRI represents a unique dataset of direct PPIs. Combining HuRI with all 
previously published systematic screening efforts at CCSB yields 64,006 binary PPIs involving 
9,094 proteins (HI-union) (Supplementary Table 9), which is approximately five-fold more PPIs 
than the entirety of high-quality binary PPIs curated from the literature (Fig. 1i). The union of Lit-
BM and HI-union represent the most complete collection of high quality direct PPI data available 
to date (http://interactome.dfci.harvard.edu/huri/). 
PPIs in HuRI vary by the number of screens and assay versions in which they were 
detected (Extended Data Fig. 2c, d). To investigate any potential relationship between these 
factors and PPI false discovery rate, we compared MAPPIT recovery rates of HuRI and Lit-BM 
PPIs found in different numbers of screens. Interestingly, both sets of PPIs show that MAPPIT 
recovery rates increase with the number of screens in which an interaction was detected 
(Extended Data Fig. 2e, Supplementary Table 10). This trend persists even when titrating Lit-
BM to higher numbers of experimental evidence (Extended Data Fig. 2f), suggesting that 
differences in PPI recovery rates are driven by factors other than veracity of a PPI. In HuRI the 
number of screens in which an interaction is detected is weakly correlated with both the size of 
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the molecular interfacial area (ρ = 0.15, P = 0.026, two-sided permutation test, n = 234) 
(Extended Data Fig. 2g) and the number of atomic contacts (ρ = 0.14, P = 0.038, two-sided 
permutation test, n = 234) (Extended Data Fig. 2h, Supplementary Table 11), suggesting that 
identification of a PPI in a screen is impacted by interaction strength and may therefore be 
reflecting ‘detectability’ rather than accuracy. Indeed, PPIs in HuRI found in at least two screens 
corresponded more often to direct PPIs within rather than between well-described stable protein 
complexes22,23 (P = 3 × 10-18, two-sided Fisher’s exact test, n = 1817) (Extended Data Fig. 2i, 3, 
Supplementary Table 12). Because the majority of PPIs in HuRI were found in only one screen, 
our data further reinforces previous observations7,24 that the protein interactome might be 
dominated by weak, more transient PPIs, that are harder to detect. PPI detectability may impact 
previous assessments of overlap between PPI datasets, as well as estimates of interactome 
size. 
 
Multiple layers of functional relationships between proteins in HuRI 
Based on the observation that HuRI is enriched in direct PPIs, we hypothesize that proteins in 
HuRI with similar interaction interfaces should share a significant number of their interaction 
partners. For example, retinoic acid receptors RXR-γ and -β (Fig. 2a, left panel) share 
previously reported interaction partners involving binding to retinoic acid receptor RAR types25 
and oxysterol receptors26. We derived a profile similarity network (PSN) from HuRI 
(Supplementary Table 13), and found that the number of pairs of proteins in HuRI with similar 
interaction profiles is significantly higher than random (P < 0.01, one-sided empirical test) 
(Extended Data Fig. 4a) and proteins of overall higher sequence identity tend to exhibit higher 
interaction profile similarities (P < 0.01, one-sided empirical test) (Extended Data Fig. 4b). 
However, proteins with a tendency to share interaction partners often have interaction interfaces 
that are similar, as opposed to complementary, and therefore tend not to interact, unless both 
proteins originate from the same ancestral protein that was able to self-interact27 (Extended 
Data Fig. 4c). Indeed, only 5% of the proteins found to interact in HuRI share more than 10% of 
their interaction partners. HuRI and the PSN display significant enrichment to link proteins of 
similar function (P < 0.01, one-sided empirical test) (Fig. 2b, Extended Data Fig. 4d, e) and both 
contain much higher numbers of functional modules28 compared to our previously published 
interactome maps10,11 (Fig. 2c). Because HuRI and the PSN display little link overlap but both 
are functionally enriched, this suggests that HuRI and the PSN complement each other in 
revealing functional relationships between proteins.  
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As shown above, global sequence identity between two proteins is indicative of shared 
interaction interfaces, however, it likely fails to identify pairs of proteins whose shared interaction 
interface is small. Indeed, 50% (502) of all pairs of proteins in HuRI with interaction profile 
similarities ≥ 0.5 exhibit less than 20% sequence identity, showing that the functional 
relationships between proteins cannot necessarily be identified by sequence identity. One such 
pair of proteins is the endoplasmic reticulum (ER) transmembrane protein TMEM258 and the 
uncharacterized protein C19ORF18, which display a sequence identity of only 10% but share 
80% of their interactors (Fig. 2a, right panel). TMEM258 catalyzes the first step in N-
glycosylation of proteins in the ER and might play a role in protein translocation across the ER29. 
Roles in protein transport and ER function have also been ascribed to two of the four shared 
interaction partners, ARL6IP130 and IER3IP131, suggesting that C19ORF18 as well as the other 
two shared yet unstudied interaction partners MFSD6 and AC012254.2 might contribute to ER-
related functions of protein maturation and transport. 
 
Uncharted network neighborhoods of disease-related genes 
Unlike Lit-BM, HuRI was generated by systematically testing pairs of proteins for interaction. 
While Lit-BM is highly biased towards the most highly studied genes10, HuRI covers the 
genome-by-genome space, as ranked by number of publications, more uniformly and at 
increased depth compared to Lit-BM and our previous screening efforts (Fig. 3a). Considering 
these differences in interactome space coverage, we find that among the best-studied genes, 
where Lit-BM is most complete, the agreement between Lit-BM and HuRI is highest, with ~40% 
of the PPIs in HuRI being previously identified (Fig. 3b). Because of its uniform coverage, HuRI 
substantially expands the set of genes of biomedical interest for which high-quality direct PPI 
data is available (Fig. 3c, Extended Data Fig. 4g), and extends their network neighborhood to 
previously uncharted regions of the protein interactome (Fig. 3d, Extended Data Fig. 4g).  
As previously shown10,32, study bias can skew interactome coverage and the assessment of 
systems properties of genes. Using HuRI, we find no evidence of reported correlations between 
a protein’s number of interaction partners (degree) and various gene properties, i.e. lethality33,34, 
loss-of-function intolerance1, fitness effect35, and age36,37 (Fig. 3e-g). Moreover, these 
correlations weaken for protein complex and Lit-BM interactome maps when they are corrected 
for confounding protein expression or study bias, respectively (Fig. 3e-g). These results 
highlight the value of HuRI as a uniformly-mapped reference for the study of systems properties 
of genes and networks. 
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Identification of subcellular compartment-specific roles of PPIs 
Proteins are localized to specific subcellular compartments to exert functions that can depend 
both on the subcellular environment and the local PPI network. Despite available proteome-wide 
datasets on the localization of individual proteins38, experimental determination of cellular 
localization-specific PPI networks remains challenging39. We find that proteins localized to a 
diverse range of subcellular compartments are evenly represented in HuRI (Fig. 4a) suggesting 
that cellular localization-specific PPI networks can be inferred for many different cellular 
compartments via integration of HuRI with available protein localization data.  
One such compartment, extracellular vesicles (EVs), has been intensively studied using 
proteomics approaches40, however, our understanding of the molecular mechanisms that lead 
to protein recruitment into EVs and subsequent secretion, remains limited. The subnetwork of 
interactions between EV proteins (Fig. 4b) shows significantly higher connectivity in HuRI than 
in degree-controlled randomized networks (P < 0.001, one-sided empirical test) (Fig. 4c) 
enabling prediction of EV recruiters using the number of EV interaction partners. Seven of the 
top 20 most connected proteins in this EV network have established roles in EV biogenesis or 
cargo recruitment41,42 (Fig. 4b). SDCBP (syntenin-1) functions in ESCRT-dependent exosome 
generation and its knockout shows reduced EV production43. SDCBP has 48 PPIs with other EV 
proteins and is frequently detected in EVs (Fig. 4b), suggesting that it regulates recruitment of 
interacting proteins to EVs. To test this hypothesis (Fig. 4d), we knocked out SDCBP in the 
U373vIII cell line (Extended Data Fig. 5a) and found that three of six SDCBP partners detected 
in the U373vIII EV proteome, CALM1, CEP55 and HPRT1, displayed significantly reduced (P < 
0.05, one-sided empirical test, fold change < 0.66) (Fig. 4e) protein levels in EVs in the SDCBP 
knockout line. In contrast, only 15% of the non-interaction partners of SDCBP were reduced (P 
< 0.05, one-sided empirical test) (Extended Data Fig. 5b). Thus, SDCBP may play a role in the 
recruitment of proteins into EVs, highlighting the potential value of HuRI in studying protein 
function within specific subcellular contexts. 
Despite a significant tendency for interactions in HuRI to link proteins localized to the same 
compartment (P < 0.01, one-sided empirical test) (Fig. 2b), a considerable number of 
interactions were identified between proteins not reported to co-localize. We find that HuRI PPIs 
between non-colocalized proteins tended to connect proteins from compartments that 
significantly overlapped (P < 0.001, one-sided empirical test) (Extended Data Fig. 5c-e). This 
suggests that the lack of co-localization results from incompleteness of the underlying 
localization annotation and that HuRI could prove useful in predicting additional protein locations 
and dynamics.  
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Principles of tissue-specific cellular function 
Despite recent advances in systematic genome-wide identification of tissue-preferentially 
expressed genes (TiP genes)2,44, we lack a concrete understanding of how the surprisingly 
small set of TiP genes operate together and coordinate their activity with the core housekeeping 
cellular machinery to mediate tissue-specific functions. Insights can be obtained from 
investigating the tissue-specific network context of TiP proteins, inferred from integrating protein 
interactome data with tissue transcriptomes. However, we find that protein complex7–9 and 
literature-curated interactome maps45 as well as our previously published binary PPI 
datasets10,11 are strongly depleted for TiP proteins, whereas they are well-represented in HuRI, 
making it the most suitable interactome map available to study the network context of TiP 
proteins (Fig. 5a, Extended Data Fig. 6a). 
System-wide properties of TiP proteins can be determined by assessing their connectivity 
and centrality in a PPI network compared to “non-TiP” proteins46. In HuRI we observe that TiP 
proteins can engage in as many PPIs and be as central in a PPI network as the more uniformly 
expressed proteins (degree: Spearman ρ = 0.005, centrality: Spearman ρ = -0.008) (Extended 
Data Fig. 6b), contrary to previous observations derived from literature-curated PPI networks47–
49. This result, paired with the fact that PPIs mediated by a TiP protein are effectively also 
tissue-specific, leads to the finding that the protein interactome as characterized by HuRI is 
more tissue-specific than the expressed genome (Fig. 5b). This indicates that substantial 
information on tissue-specific function can only be obtained from the interactome. The opposite 
is observed for Lit-BM, likely owing to its bias against TiP genes (Fig. 5b). 
To investigate the local network neighborhoods of TiP proteins within their respective tissue 
context, we used HuRI to derive protein interactome maps for 35 tissues2,50 (Supplementary 
Table 14). Each contained an average of 25,000 PPIs that link proteins expressed in that tissue 
(Extended Data Fig. 6c, d). Within each tissue PPI network, we focused on the interactions 
involving at least one TiP protein (Fig. 5c). The TiP PPI networks show extensive interactions 
between TiP proteins and non-TiP proteins, with very few TiP-TiP PPIs dispersed through the 
network, as exemplified for brain (Fig. 5c, d). Indeed, TiP-TiP PPIs in brain are not enriched, nor 
is the average shortest path among TiP proteins shorter than in degree-controlled randomized 
networks (P > 0.05, empirical test) (Fig. 5e). Using either metric, TiP proteins were found to be 
significantly close to each other in six of 35 tissues, in four of which signals were dominated by 
clusters of specifically expressed keratins or late-cornified envelope proteins (Extended Data 
Fig. 6e). Overall, these results provide support for a model in which tissue-specific functions 
emerge through interactions between TiP proteins and more uniformly expressed members of 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605451doi: bioRxiv preprint first posted online Apr. 10, 2019; 
11 
the basic cellular machinery, presumably modulating and adapting common cellular processes 
for cellular context-specific needs51. 
To further investigate functional roles of the identified interactions in HuRI between the basic 
cellular machinery and preferentially expressed proteins, we selected apoptosis, a biological 
process with known cell type and developmental stage-specific homeostatic roles52,53. We 
predicted apoptosis-related functions for proteins based on an enrichment of known apoptosis 
regulators in the protein network neighborhood (Supplementary Table 15). Among the ten most 
significant predictions were five proteins with demonstrated roles in apoptosis (BCL2L254, 
BCL2L155, LCN256, BCL2A157 and BCL2L1058) supporting the validity of the approach. Among 
the genes with predicted apoptosis function were C6ORF222, OTUD6A, and NHSL2, three 
uncharacterized and highly specifically expressed genes (Extended Data Fig. 6f, g). To test the 
predicted role of the three genes in apoptosis, we assessed their impact on cell viability upon 
over-expression. Abundance of OTUD6A negatively correlated with time-of-death after addition 
of TRAIL (TNF-related apoptosis-inducing ligand, P = 0.012, two-sided, empirical test, n = 40 
cells) (Extended Data Fig. 6h), contrary to expression of OTUD6A alone (Extended Data Fig. 
6h, Supplementary Table 16). This suggests that OTUD6A participates in the apoptosis 
pathway but is not itself an inducer of cell death. We found OTUD6A to interact with DYNLL1 
and 2 (Extended Data Fig. 6i), two integral members of motor complexes that sequester 
BCL2L11 and BMF, two “BH3-only” proteins, to the cytoskeleton thereby inhibiting their pro-
apoptotic function59,60. OTUD6A expression is generally repressed with low expression in 
eosinophils61–63 (Extended Data Fig. 6f) and significant upregulation in response to Decitabine 
treatment, a drug effective against acute myeloid leukemia63,64. Thus, OTUD6A might exert an 
apoptosis sensitization function via transcriptional activation in a haematopoietic cellular context 
(Extended Data Fig. 6i).  
We were unable to generate a sufficient number of cells expressing C6ORF222 or NHSL2 
to perform the cell death assay. However, C6ORF222 contains a BH3 domain65 that likely 
mediates the binding to BCL2L2 and BCL2L1 identified in HuRI (Extended Data Fig. 6i). The 
interaction between C6ORF222 and the apoptosis regulator MAPK9 identified in HuRI 
(Extended Data Fig. 6i) was also reported in BioPlex (unpublished released BioPlex data8) 
providing further support for a functional role of C6ORF222 in apoptosis, probably in a digestive 
tract-specific cellular context (Extended Data Fig. 6g,i). OTUD6A and C6ORF222 represent two 
examples of specifically expressed genes that might adapt the basic apoptosis machinery to 
cellular context-specific needs. 
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Molecular mechanisms of tissue-specific Mendelian diseases 
Many Mendelian diseases display highly tissue-specific phenotypes, which are rarely explained 
by tissue-specific expression of genes carrying disease-associated mutations66,67 (Fig. 5f, 
Extended Data Fig. 6j). Such mutations have been shown to broadly or specifically affect the 
formation of PPIs involving the mutated protein68. Perturbations of PPIs between uniformly 
expressed disease-associated proteins and TiP proteins in the corresponding affected tissues 
have been suggested to underlie the tissue-specific phenotypes of those diseases67. Searching 
the HuRI-derived tissue PPI networks, we find 130 such PPIs involving 63 distinct non-TiP 
causal proteins and 94 TiP proteins (Fig. 5g). Although we do not observe a significant trend for 
PPIs between causal proteins and TiP proteins to occur more often than in random networks 
(Extended Data Fig. 6k), this does not rule out the possibility that perturbations of some of these 
interactions mediate tissue-specific phenotypes of Mendelian diseases. 
To further explore this hypothesis, we experimentally tested whether pathogenic variants 
associated with the corresponding Mendelian diseases were able to perturb these PPIs. Of ten 
causal proteins tested, seven showed perturbation of PPIs to preferentially expressed 
interaction partners in the corresponding “disease tissues” (Fig. 5g-h, Extended Data Fig. 7, 
Supplementary Table 17). One example is the gene PNKP, mutations in which have been 
associated with microcephaly, seizures and developmental delay69. PNKP, a polynucleotide 
kinase 3’-phosphatase, is involved in DNA damage repair69. The well-established pathogenic 
mutation (Glu326Lys) affects neither the DNA kinase nor DNA phosphatase activity of PNKP, 
rendering the mechanism of pathogenicity unclear70. We observed that Glu326Lys perturbed 
PPIs with two partners preferentially expressed in the brain, SYNGR1 and TRIM37, whereas the 
benign mutation Pro20Ser71 did not affect any of these PPIs (Fig. 5i). Interestingly, TRIM37 is 
known to facilitate DNA repair72 suggesting a potential mechanism through which the 
perturbation of this interaction might affect the brain-specific DNA repair function of PNKP.  
In two other cases, CTNNA3 and SUCLA2, the identified TiP interaction partners TRIM54 
and ARL6IP1, respectively, themselves cause similar diseases with overlapping symptoms73,74, 
reinforcing the likely pathogenic relevance of the interactions. Overall, this study yields 
hypotheses of molecular mechanisms for otherwise unexplained tissue-specific phenotypes of 
seven Mendelian diseases (Fig. 5h) and demonstrates the utility of HuRI as a reference to study 
biological mechanisms within specific disease contexts.  
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Exploration of isoform-specific protein function during development 
Transcripts of most human genes undergo alternative splicing, leading in many cases to altered 
protein sequences. Due to loss or gain of protein interaction-mediating domains or linear motifs, 
alternative isoforms of the same gene have been found to differ in their interaction profiles75,76. 
Modulation of cellular function by alternative splicing is especially prevalent during 
developmental processes and in some select adult tissues such as brain or testis77, yet most 
alternative splice products remain uncharacterized. Although we screened only one isoform per 
gene, HuRI is unique among available human protein interactome maps in providing information 
about the exact full-length protein sequence of each interaction partner. To aid in the functional 
characterization of alternative splice products, we aimed at identifying isoforms of a gene with a 
dominant-negative effect on overall gene function. We combined HuRI with isoform-dependent 
expression data78 to identify genes with isoforms expressed in the same tissue. These genes 
were further filtered to identify those for which an alternative isoform was predicted to lose some 
but not all of its interaction-mediating domains79, thus likely to lose some but not all of its 
interaction partners compared to the isoform screened in HuRI76 (Fig. 6a).  
Of the 192 candidate genes identified (involving known examples of altered alternative 
isoform function, Supplementary Table 18), we further considered NCK2. NCK2 displayed a well 
studied principal (long) isoform80,81 and an uncharacterized alternative (short) isoform in which 
three of four predicted interaction-mediating domains are lost (Fig. 6b). Both isoforms are 
expressed in brain, suggesting specific functional modulation by alternative splicing during brain 
development (Fig. 6c, Extended Data Fig. 8a, Supplementary Table 19). Known brain-specific 
functions of NCK2 include synaptic transmission82, organization of neuronal circuits83, and axon 
guidance84,85. Interestingly, a variant associated with autism was found near a splice site of the 
alternative exon of NCK2 further suggesting a functional implication of alternative splicing of 
NCK2 in brain development86,87. 
Pairwise testing interaction partners of the long isoform of NCK2 with the short isoform 
confirms the loss of some but not all interaction partners (Fig. 6d) consistent with the retention 
of one interaction-mediating domain in the short isoform (Fig. 6b). We used zebrafish as a 
model to test the hypothesized dominant-negative function of the short isoform over the long 
isoform of NCK2 during brain development (Extended Data Fig. 8b-d). We successfully knocked 
down both isoforms of zNCK2B in zebrafish using morpholinos (Extended Data Fig. 8e) to 
measure the impact of loss of zNCK2B on the size of the developing zebrafish brain. While 
expression of the hNCK2 long isoform in zebrafish under knockdown condition of the 
endogenous zNCK2B gene partially rescued the phenotype, expression of the short isoform did 
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not (Fig. 6e, Extended Data Fig. 8f, g). Furthermore, expression of the short isoform of hNCK2 
in zebrafish brain led to a significant decrease in the size of the developing zebrafish brain, an 
effect that was not observed with expression of the long isoform of hNCK2 (Fig. 6e). These 
observations support the predicted dominant negative effect of the short isoform of NCK2 and 
highlight the power of HuRI to serve as a reference to study isoform-specific protein function in 
a developmental cellular context. 
 
Perspectives 
By systematically screening about 90% of the protein-coding genome for binary PPIs using a 
panel of Y2H assays, we generated HuRI, a first reference map of the human protein 
interactome. Via integration of HuRI with contextual genome, transcriptome and proteome data, 
we infer cellular context-specific PPI networks that prove to be powerful resources in delineating 
aspects of cellular context-specific function and organization. Inferred cellular context-specific 
interactome maps will further gain in accuracy from advances in transcriptomics and proteomics 
technologies with increasing sensitivities down to the single cell level4. Transition from discrete 
(presence/absence) towards more continuous network models may be achieved by using 
expression levels to assign weights to interactions88, and further improved with large-scale 
measurements of interaction strengths9. Integration of inferred cellular context-specific networks 
with experimentally-derived cellular context-specific molecular interaction data89 will be critical to 
further refine those models. Future efforts to generate binary protein interactome maps will 
benefit from development of new PPI assays16 capable of identifying PPIs for the proteins still 
absent from HuRI. New cloning and faster screening technologies90,91 are needed to take 
interactome mapping from testing one isoform per gene to the ensemble of proteoforms 
generated within the cell. Although multiple challenges remain to be solved for a complete and 
context-specific map of protein functions, interactions, and higher-level organization, HuRI 
provides an unbiased genome-scale scaffold with which to coordinate this information as it 
emerges. 
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METHODS 
 
Construction of Reference ORFeome and definition of screening space 
(space III)  
 
Selection of existing clones 
We supplemented our human ORFeome collection hORFeome version 7.1 (v7.1) 
(http://horfdb.dfci.harvard.edu/hv7)92 with clones from additional genes from the ORFeome 
Collaboration93 (http://www.orfeomecollaboration.org), DNASU plasmid repository94 
(https://dnasu.org) and other collaborators. All clones are in Gateway compatible entry vectors 
with spectinomycin or kanamycin resistance markers, as appropriate. While native stop codons 
of most clones have been removed, 617 clones contain native stop codons. 
To select a single Open Reading Frame (ORF) for genes with multiple ORFs available, 
for each gene, we aligned the sequences of the corresponding ORFs to human genome 
GRCh37 using BLAT95 (v36x1) and chose the longest ORF with more than 95% of its sequence 
aligned to the genome. If no such ORF was available, we chose the ORF with the highest 
percentage of alignment to the genome. 
 
Cloning of new ORFs 
After collecting available ORFs from different resources, about ~3,000 human protein-coding 
genes remained uncovered (no ORF available). To obtain ORF clones for these missing genes, 
we attempted RT-PCR on a pool of cDNA libraries from brain, heart, and liver ordered from 
Biochain (Human Adult Normal Tissue: Brain, catalog number C1234035, lot number C203351; 
Human Adult Normal Tissue: Heart, catalog number C1234122, lot number B901100; Human 
Adult Normal Tissue: Liver, catalog number C1234149, lot number C203352). We designed 
primers for all the missing genes for which we could find coding sequences from RefSeq96 
(https://www.ncbi.nlm.nih.gov/refseq; downloaded April 13th, 2015). In total, we attempted 2,257 
primer pairs and successfully cloned 481 ORFs into pDONR223 vector, all without native stops. 
The sequences of the clones were verified using Illumina sequencing. We named the combined 
collection hORFeome v9.1. 
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Definition of the human protein-coding genome 
GENCODE97 annotation (ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_27) and 
DNA and protein sequences were filtered for information on transcript entries. After removing 
PseudoAutosomal Regions on the Y chromosome (PAR) genes, all genes of gene_type 
“protein_coding” with annotated transcripts yielded the 19,818 protein-coding genes used in this 
study. External datasets were mapped via gene or protein IDentifiers (IDs) to the Ensembl gene 
ID space, and genes, proteins, or transcripts that did not map were removed. 
 
Mapping of ORFs to GENCODE release 27 
To assign Ensembl gene IDs to ORFs in the hORFeome v9.1 collection, we aligned ORFs to 
protein-coding transcripts in GENCODE97 and determined the best match for each ORF-
transcript pair. Briefly, ORF protein sequences were aligned to all protein sequences of protein-
coding transcripts using BLASTP98 (NCBI BLAST v2.2.30) with default parameters. Alignments 
were further refined using MUSCLE99 (v3.8.31; default parameters). For each Ensembl gene, 
we kept only alignments with identity ≥ 95%, ORF coverage ≥ 50%, transcript coverage either ≥ 
50% or with at least two exons covered. The best match was determined based on the 
combination of ORF coverage, transcript coverage and alignment identity.  
Each ORF could generally be assigned to only one Ensembl gene, but where alignments 
were fully identical among different genes (e.g. histones), the ORF was assigned to multiple 
genes. Finally, we removed 33 ORFs containing known disease mutations based on HGMD100 
v2016 annotation. Using this pipeline, hORFeome v9.1 was matched to 17,408 protein-coding 
genes (Supplementary Table 20). 
 
Generation and benchmarking of Yeast Two-Hybrid (Y2H) assay versions 
 
Vector design 
To generate pDest-AD-AR67 [Activation Domain (AD) at C-terminus (C-term) with yeast 
centromere (CEN)], a fragment encoding an ADH1 promoter, Gateway recombination cassette, 
and C-terminal AD was PCR amplified from pGADCg101 using forward primer AP36 (5’ 
GAAGGCTTTAATTTGCAAAGCTCGGGATCCGGGCCCCCCCTCGAGATCCGcatctattgaagtaat
aataggcgcatg 3’) and reverse primer AP37 (5’ 
CAACCTTGATTGGAGACTTGACCAAACCTCTGGCGAAGAAGTCCAAAGCTctgaataagccctcgt
aatatattttcatg 3’) and cloned into EcoRI (New England Biolabs, NEB) and SalI (NEB) digested 
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pDEST-AD via homologous recombination gap repair in yeast. To generate pDest-AD-AR68 
(AD at Cterm with yeast 2µ), the same fragment encoding the ADH1 promoter, Gateway 
recombination cassette, and C-terminal AD was instead PCR amplified from pGADCg using 
forward primer AP36 and reverse primer AP38 (5’ 
GCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGcatctattgaagtaat
aataggcgcatg 3’) and cloned into NotI- and XmaI-digested (NEB) pDest-AD-QZ213 via 
homologous recombination in yeast. See Supplementary Table 21 for details on vector design 
and Y2H assay versions. 
 
Benchmarking pairwise test performance  
Assay versions were benchmarked by Y2H using a positive reference set of 92 well-
documented interacting human protein pairs (Positive Reference Set; PRS v1) and a set of 92 
random human protein pairs (Random Reference Set; RRS v1), as previously described14. 
Briefly, haploid yeast strains Y8800 and Y8930 carrying plasmids expressing AD and DB 
reference set fusions, respectively, were mated overnight and diploid selection was performed. 
Diploids were spotted onto Synthetic Complete media without Leucine, Tryptophan and 
Histidine with 1 mM 3-Amino-1,2,4-triazole (SC-Leu-Trp-His+1 mM 3AT for assay versions 1 & 
2) or SC-Leu-Trp-His+10 mM 3AT (for assay version 3) solid media, incubated at 30oC for 4 
days, and interactions were scored based on the strength of GAL1::HIS3@LYS2 reporter 
activation. Pairs that displayed AD-independent GAL1::HIS3@LYS2 autoactivation were 
designated as negatives. 
 
Benchmarking screening capabilities of Y2H assay versions on a test space 
For each assay version we performed several screens of a test space10 covering ~1% of the 
total space (~2,000 DB’s against ~2,000 AD’s) to adjust the protocol for high-throughput 
screening. Based on that, we were able to calculate how many screens per assay version are 
needed to reach saturation and how many new pairs are found by screening a space several 
times. For Y2H assay version 1, 2 and 3, we performed 12, 3, and 6 screens, respectively. The 
screens were performed and validated as described below in the Y2H screening, retest, and 
validation sections. 
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Subcloning into Y2H vectors 
 
Preparation of Y2H destination clones by 1-to-1 Gateway cloning 
ORFs from the hORFeome v9.1 collection were transferred by Gateway recombinational cloning 
(Invitrogen) into Y2H destination vectors pDEST-DB and pDEST-AD-CYH2 to generate DB and 
AD-hybrid proteins (DB-ORF and AD-ORF, respectively), as described previously102. In addition, 
all ORFs were transferred into pDest-AD-QZ213 for assay version 2 and all ORFs without a 
stop codon into pDest-AD-AR68 for assay version 3. 
 
Preparation of Y2H destination clones by en masse Gateway cloning 
To increase the throughput and efficiency of the cloning, we transferred the majority of the 
clones into the pDest-AD-AR68 vector en masse. To enable future use in the barcode fusion 
genetics Y2H system90. As described previously90,91, we generated randomly barcoded Y2H 
destination plasmid pools and carried out en masse Gateway LR reactions, bacterial 
transformations, colony pickings, and sequencing to identify ORFs and barcodes. After 
obtaining the raw sequencing reads, we ran Illumina bcl2fastq (v2.20 with options “--no-lane-
splitting -r 3 -p 10 -w 3”) to demultiplex all the reads into different plates according to the i5/i7 
index sequences. Extracting well-tag from each read, identified by locating conserved flank 
sequences, allowed assignment of reads from each plate to the corresponding well of origin. 
Full length (24-26 nt) barcodes within one base-pair mismatch were merged to identify the 
dominant barcode for each well. ORF reads in each well were aligned to reference ORF 
sequences via Bowtie 2103 (v2.2.3). For wells containing more than one clone, we filtered all the 
ORF and barcode pairs found in each well by calculating the percentage of reads aligned to 
each ORF. Only dominant barcoded-ORFs were selected, as defined by the ORF with the 
highest fraction of reads (at least, 20 reads and 20%) and ≥5X more reads than those for the 
second dominant ORF. About 1% of clones were validated by Sanger sequencing with ≥95% 
validation rate. 
 
Primary screening 
 
Yeast strains and transformation 
Competent yeast strains Y8800, mating type MATa, and Y8930, mating type MATa, both 
harboring the genotype leu2-3,112 trp1-901 his3Δ200 ura3-52 gal4Δ gal80Δ GAL2::ADE2 
GAL1::HIS3@LYS2 GAL7::lacZ@MET2cyh2R were transformed with individual AD-ORF and 
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DB-ORF constructs respectively, and plated onto SC-Trp or SC-Leu to select for AD-ORF or 
DB-ORF plasmids102. 
 
Auto-activator identification and removal 
Prior to Y2H screening, haploid DB-ORF yeast strains were tested for auto-activation of the 
GAL1::HIS3 reporter gene in the absence of any AD-ORF plasmid. Individual DB-ORF yeast 
strains showing growth in a spotting assay on SC-His-Leu+3AT media were considered auto-
activators and removed from the collection of strains to be screened. 
 
Y2H screening 
Fresh overnight cultures of individual Y8930:DB-ORF yeast strains (bait) were mated against 
Y8800:AD-ORF libraries containing ~1,000 different Y8800:AD-ORF yeast strains (prey). After 
overnight growth at 30ºC in liquid rich medium (YEPD), mated yeast cells were transferred into 
liquid SC-Leu-Trp media to select for diploids. After overnight incubation at 30ºC diploid yeast 
cells were spotted onto SC-Leu-Trp-His+3AT solid media to select for activation of the 
GAL1::HIS3 reporter gene. In parallel, diploid yeast cells were transferred onto SC-Leu-
His+3AT solid media supplemented with 1 or 10 mg/l CHX for assay version 1 or 2 and 3, 
respectively. All AD-ORF plasmids carry the counter-selectable marker CYH2, which allows 
selection on CHX-containing medium of yeast cells that do not contain any AD-ORF plasmid in 
order to identify spontaneous DB-ORF auto-activators102. After 72h incubation at 30ºC, yeast 
that grew on SC-Leu-Trp-His+3AT media but not on SC-Leu-His+3AT+CHX media were picked 
into SC-Leu-Trp overnight and then processed to determine the identity of the respective bait 
and prey proteins. 
 
Yeast colony PCR and sequencing 
Because each DB-ORF yeast strain was mated against a library of ~1,000 AD-ORF yeast 
strains in the first-pass screens, one bait protein could interact with more than one prey proteins 
per mini-library. To account for this, we picked between three and five colonies (primary 
positives) from each growth spot on SC-Leu-Trp-His+3AT media to 96-well plates. Primary 
positive colonies were processed as described102 to generate lysates for PCR. Three microliters 
of diluted lysate was used as a template for PCR amplification to generate DB-ORF and AD-
ORF PCR amplicons.  
To cost-effectively identify both bait and prey proteins for hundreds of thousands positive 
colonies, we developed a method called SWIM-seq (Shared-well Interaction Mapping by 
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sequencing). Using SWIM-seq, we took advantage of next generation sequencing technology 
and pooled DB-ORF and AD-ORF PCR products that contain well-specific and plate-specific 
nucleotide sequences from tens of thousands colonies together in one sequencing run. Briefly, 
PCR was performed using AD and DB well index primers together with universal primers (see 
table below). All PCR was done using Platinum Taq (Life Technologies). After PCR, the 
products from each PCR plate were pooled into one single well in a 96-well plate (SWIM plate). 
The SWIM plates were purified (Qiagen, PCR Purification Kit) and processed to make an 
Illumina sequencing library, during which Illumina adapter sequences, i7 and i5, were 
incorporated as plate indexes. The library was then paired-end-sequenced using an Illumina 
platform (MiSeq or NextSeq 500). See Supplementary Table 22 for the primers used for the 
different Y2H assay versions.  
 
Identification of pairs of AD-ORF and DB-ORF 
We developed a computational pipeline to process demultiplexed paired-end reads and identify 
the matching ORF pairs corresponding to Y2H-positive colonies. Paired-end reads are in a fastq 
format, with one read, R1, containing a part of the ORF sequence and the other paired read, 
R2, containing the well index. Briefly, we used Bowtie 2103 (v2.2.3) to align all R1 reads to 
reference sequences and extracted the well-identifying indices from the R2 reads. AD-ORFs 
and DB-ORFs that shared the same well indices were paired together. Pairs identified from the 
primary screen were calls FiPPs (First Pass Pairs). To identify likely true interacting pairs, we 
developed a “SWIM score” S that takes into account the AD and DB reads in each well, total 
reads returned from the sequencing run, and other factors.  
 
  
where x and y are read counts of an AD-ORF and DB-ORF in a given well respectively, a and d 
are total read counts of all aligned AD-ORF and DB-ORF in that well, and M and N are pseudo-
counts for AD and DB respectively, which were constant for each sequencing batch but varied 
for different batches. 
  We then selected FiPPs for pairwise test using a cutoff that balances the risk of testing 
too many FiPPs that are not protein-protein interactions (PPIs) versus not testing too many 
FiPPs that are actual PPIs. The cutoff varied for different screens and sequencing runs to 
accommodate slight variations in the screening and sequencing protocol.  
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Pairwise test 
 
Design of pairwise test and scoring 
No FiPP is considered a PPI and released before it has been verified in a pairwise test using 
Y2H. For all FiPPs, each protein was picked from the stock collection and mated with its 
partner. This experiment was done in quadruplicate, with yeast spotted on both SC-Leu-Trp-
His+3AT plates and SC-Leu-His+3AT+CHX to test for spontaneous auto-activation. As positive 
and negative controls in each test batch, 92 pairs from PRS v1, 250 randomly selected Lit-BM 
pairs (literature binary multiple pairs), and 250 pairs of proteins randomly selected from the 
search space were included. Experiments were considered successful if at most 1% of the 
random protein pairs and 10% or more of the Lit-BM or PRS v1 pairs scored positive. Positive 
and negative controls were combined in the same batches with FiPPs and scored blindly. To 
ensure the mating of the corresponding plates with each other (AD-X with DB-Y) and identify 
any potential plate rotations or swaps, each retest plate has a unique pattern of empty wells. We 
developed a pipeline to semi-automate the scoring of growing yeast in 384 or 96 format. 
Growing yeast colonies were first scored automatically by software that uses the python library 
Colonyzer104 to process the images. The scores were then manually checked prior to saving 
and pixel intensities were used to estimate the strength of growth. Both retest plates and CHX 
control plates were independently scored and scores combined to produce a final score of each 
well. A pair was scored invalid (NA) for 96-well format if the well was unscorable (contaminated, 
not spotted, etc.); or, if in 384 format, if at least 2 of the 4 quadruplicates were unscorable on the 
retest plate; or, if the corresponding well on the CHX plate was unscorable. If a pair was not 
scored as NA but grew at least as strongly on the CHX plate compared to the growth on the 
retest plate (average of quadruplicates), then it was scored as a spontaneous auto-activator. If a 
pair was neither NA nor an auto-activator and showed growth in at least 3 of 4 replicates on the 
retest plate, then it was scored as positive; otherwise, negative.  
 
Treatment of pairs scored as spontaneous auto-activators 
Because validation data has suggested that the CHX control is over-sensitive for 2µ vectors and 
removes many actual PPIs, we performed one more pairwise test for pairs that scored as 
spontaneous auto-activators in the pairwise test in assay versions 2 and 3. For these retests, 
the DB-ORF was separately mated with an “AD-nul” plasmid without any ORF in the cloning 
site. If a yeast colony grew more strongly when mated to the corresponding AD-ORF than the 
AD-null strain, we “rescued” this PPI and added it to the dataset after sequence confirmation. 
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Sequence confirmation of positive pairs from pairwise test 
To guide the picking of all positive pairs for sequence confirmation, a “picking map” with all 
positive pairs was generated by the scoring software and printed. Picked pairs were lysed and 
SWIM-PCR was performed as described in the above section. Illumina reads were processed 
via the computational pipeline described above. Only pairs identified from the pipeline that 
matched the tested ORF pairs previously scored as positive were considered PPIs. 
 
Validation of screens with orthogonal PPI assays 
 
Design of validation experiments 
To validate each of the nine screens of Space III, we randomly selected ~340 positives from 
each screen and tested them in several batches using two assays, MAPPIT (MAmmalian 
Protein-Protein Interaction Trap) and GPCA (Gaussia princeps luciferase protein 
complementation). For each batch, we included ~200 randomly selected PPIs from Lit-BM as 
PRS and ~400 pairs of proteins randomly selected from the search space as RRS. For each 
pair, a random bait-prey configuration was assigned. All tested pairs and control pairs were 
combined in batches and tested blindly.  
 For the test space validation, unlike in the main screen where we chose PPIs for each 
screen, we randomly chose PPIs from all positive pairs together regardless of which screens 
they were from. All Lit-BM PPIs (~200) and ~400 random pairs of proteins from within the tested 
space were treated as a positive reference set and a random reference set respectively. 
 
MAPPIT assay 
MAPPIT experiments were performed as previously described10. Briefly, HEK293T cells were 
grown in 384-well plates and co-transfected with a luciferase reporter and plasmids for both bait 
and prey fusion proteins. Twenty-four hours post-transfection, cells were either stimulated with 
ligand (erythropoietin) or left untreated, then incubated for an additional 24 hours before 
luciferase activity was measured in duplicate. The MAPPIT validation experiment was deemed 
valid if both bait and prey were successfully cloned into expression vectors and bait expression 
was detected. “Fold-induction” values (signal from stimulated cells divided by signal from 
unstimulated cells) were calculated for each tested pair, and two negative controls (no bait with 
prey and bait with no prey). Each tested pair was assigned a quantitative score: the fold-
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induction value of the pair divided by the maximum of the fold-induction value of the two 
negative controls. 
 
GPCA assay 
As an orthogonal validation assay, GPCA experiments were performed as described 
elsewhere16. Briefly, GPCA N1 and N2 vectors are based on two fragments of the Gaussia 
princeps luciferase with humanized codon usage (herein referred as GLuc)19. Both GLuc 
fragments were linked to the N-terminus of the tested proteins via a flexible linker polypeptide of 
20 amino acid residues, including the Gateway recombinational cloning sites. To normalize 
mRNA translation initiation, a consensus Kozak translation start sequence was added. Both 
constructs were carried by the same CytoMegaloVirus (CMV)-driven mammalian expression 
vector (pCI-neo derived, Promega) and were maintained at high copy number via the presence 
of the SV40 replication origin. 
HEK293T cells were seeded at 6x104 cells per well in 96-well, flat-bottom, cell culture 
microplates (Greiner Bio-One), and cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal calf serum at 37°C and 5% CO2. 100 ng of purified plasmid DNA 
for each protein of a pair was transfected into HEK293T cells in 96-well, flat bottom, cell culture 
plates (Greiner Bio-One) supplemented with 10% Fetal Bovine Serum (FBS) in DMEM using 
PolyEthylenImine (PEI)19. The DNA/PEI ratio (mass:mass) was 1:3. Cell culture medium was 
removed 24 h after DNA transfection, and cells were gently washed with 150 µL pre-warmed 1x 
PBS (phosphate buffered saline). 40 µL of lysis buffer was added to each well, and cell lysis 
was performed under vigorous plate shaking for 20 min at 900 rpm. Luminescence was 
measured by auto-injecting 50 µL Renilla luciferase substrate (Renilla Luciferase Assay system, 
Promega) in each well and integrating light output for 4 s using a TriStar luminometer (Berthold) 
to obtain quantitative scores. GPCA has not been performed on PPIs of screens 7, 8, and 9 
generated with Y2H assay version 3. 
 
Processing of data and calculation of validation rates 
In MAPPIT and GPCA assays, if a pair is positive or negative was determined by thresholds set 
at the 99th percentile of the RRS scores (equivalent to a 1% false discovery rate). This was 
determined separately for each experimental batch and calculated using the quantile function in 
the Python pandas library. Pairs without valid quantitative scores were dropped, and recovery 
rates were calculated as the number of positive pairs over the sum of the positive and negative 
pairs. The error bars on the recovery rates were calculated using a Bayesian model (a binomial 
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likelihood with a uniform prior), taking the central 68.27% interval of Beta (p + 1, n + 1), where p 
and n are the number of pairs testing positive and negative, respectively.  
 
Testing of PPIs in MAPPIT that were found in multiple screens and analysis of data 
Randomly sampled PPIs were selected for validation assessment from individual screens and 
from additional randomly-sampled pairs from subsets of PPIs that were defined by the number 
of screens in which the PPI was detected. Every pair in HuRI that was also in any of the 
literature curated datasets [Lit-BM / Lit-BS (literature binary singleton pairs) / Lit-NB (literature 
not binary)] was also selected for validation assessment. 
 
Processing of external transcriptome datasets: GTEx, FANTOM and Human 
Protein Atlas 
 
Genotype-Tissue Expression project (GTEx)2 v6 transcriptome data previously processed with 
the R YARN package50 was downloaded from 
http://networkmedicine.org:3838/gtex_data/gtex_portal_normalized.rds on March 15th, 2016 
and processed with R v3.5.1 to extract normalized log read count data for every gene and tissue 
sample. The median expression of every gene across all samples from a given subtype (tissue 
or cell line) was calculated and considered as the expression level of the genes in those tissues. 
A median expression cutoff of >5 was applied to consider a gene being expressed in a given 
tissue. Cell line samples were excluded and genes were restricted to the set of protein-coding 
genes (see above). The YARN package collapses the 16 brain subregions into three brain 
tissues, basal ganglia, cerebellum, and other, which have been used in this study 
(Supplementary Table 23). 
Transcripts Per Kilobase Million (TPM) from Cap Analysis Gene Expression (CAGE) 
peak data was extracted from the hg19.cage_peak_phase1and2combined_tpm.osc.txt file 
(http://fantom.gsc.riken.jp/5/datafiles/latest/extra/CAGE_peaks/; version November 11th, 2014). 
Entrez gene IDs were mapped to Ensembl gene IDs and the dataset was restricted to protein-
coding genes. For each gene from FANTOM3, we computed the mean of cage peak TPM 
values of all samples associated to any FANTOM primary cell category. Samples were mapped 
to primary cells using FANTOM SSTAR (http://fantom.gsc.riken.jp/5/sstar/). Primary cell 
categories that were considered to be biologically too similar and of close TPM expression were 
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merged. TPM values were log2 transformed and a gene was considered expressed if its value > 
0. 
RNA-seq data from 64 cell lines processed at the gene level with TPM values 
downloaded on December 1st, 2017 from the Human Protein Atlas13 (https://proteinatlas.org). 
Genes with TPM ≥ 1 were considered expressed. 
 
Computing increase of HuRI with more assay versions and screens 
 
To evaluate the number of PPIs and proteins observed as a function of the number and assay 
version of screens used, the mean of the cumulative number of PPIs and proteins across all 
matching screen combinations was used. For example, for five screens with three being assay 
version 1 and two being assay version 2, the mean number of unique PPIs was calculated for all 
combinations of any 3 of the 12 assay version 1 screens and any 2 of the 3 assay version 2 
screens. 
 
Integrative analyses with protein structural information 
 
Analysis of distances between protein termini and interaction interfaces 
We retrieved experimental structures, or either complete or domain-based models (using 
Interactome3D21 version 2018_04) involving any two proteins that have at least one interaction 
in HuRI. For each subunit in a complex structure, we defined its interaction interface as the 
residues for which the Accessible Surface Area (ASA) changed more than 1 Å2 between the 
bound and unbound state. The center of this interaction interface was determined as the Cα 
atom being closest to the center of coordinates of the interaction interface. Next, we calculated 
the distance from the N- and C-terminal Cα atoms to the center of the interaction interface. 
Importantly, we only considered protein structures with complete N- or C-termini depending on 
the analysis performed. In complexes with truncated tails, we searched for monomer structures 
with a minimum of 50% coverage and complete terminal tails. In those cases, we superimposed 
the monomers onto the respective complex subunits and calculated the distance from the 
relevant terminus to the interaction interface center. Finally, we grouped these interactions 
based on the Y2H assay version(s) in which they were detected and performed the analysis 
separately for DB and AD fusions. 
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Analysis of the fraction of PPIs in dataset that are direct 
We queried Interactome3D21 (version 2018_04) for complexes involving three or more proteins 
with experimental structure available. For all combinations of protein pairs within a complex, 
Interactome3D calculated the number of residue-residue contacts by accounting for hydrogen 
bonds, van der Waals interactions, and salt and disulfide bridges. We defined protein pairs with 
five or more contacts as direct, and remaining pairs as indirect. Separately for each given PPI 
dataset, the fraction of direct PPIs was calculated as the number of direct PPIs divided by the 
number of direct and indirect PPIs. 
 
Analysis of correlation between number of screens and interaction strength 
We downloaded from Interactome3D21 (version 2018_04) the experimental structures involving 
any two proteins in HuRI (Human Reference Interactome). For each complex structure, we 
calculated the interaction interface area by subtracting the ASA in the bound state from the total 
ASA of the unbound proteins and by dividing the result by two. Additionally, we calculated the 
number of residue-residue contacts as explained above. Finally, we grouped the protein pairs 
by the number of HuRI screens in which an interaction was detected. 
 
Retrieval and processing of other interactome datasets 
 
Construction of Lit-BM  
Literature curated datasets were derived from the Mentha resource45, which aggregates 
literature-curated PPIs from five source databases: MINT105, IntAct106, DIP107, MatrixDB108 and 
BioGRID109. The data downloaded from Mentha was dated August 28th 2017. Data was filtered 
to have valid IDs for the UniProt accession numbers, Pubmed IDs and PSI-MI terms. Each 
piece of evidence for a protein pair must consist of a Pubmed ID and an interaction detection 
method code in the PSI-MI controlled vocabulary110. Duplicated evidence arises in cases where 
different source databases curate the same paper. We merged duplicated entries for each pair, 
as detected by multiple pieces of evidence with the same Pubmed ID and experimental 
interaction detection codes which are either the same or have an ancestor-descendent 
relationship in the PSI-MI ontology. (In the latter case, the more specific descendent term was 
assigned to the merged evidence.) In order to select the subset of PPIs corresponding to binary 
interactions (as opposed to co-complex associations) we developed a manual classification of 
the PSI-MI interaction detection method110 terms, which define the experimental technique used. 
Our classification has been updated since previous versions, in order to cover new experimental 
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methods which have been added to the controlled vocabulary in the intervening time. The 
methods are classified into three categories; ‘invalid’, ‘binary’ and ‘indirect’. Where ‘invalid’ 
corresponds to terms that are not considered valid experimental protein-protein interaction 
detection methods, ‘binary’ to terms that detect binary protein-protein interactions and ‘indirect’ 
to terms that detect potentially indirect interactions. An example term in the first category is 
“colocalization”. All PPI evidences annotated with “invalid” terms are removed and not 
considered. The other two categories are used to divide the protein pairs in the literature-
curated dataset into three categories, as follows. If a pair has no evidence that correspond to a 
binary method it is classified as Lit-NB, if a pair has only one piece of evidence with a binary 
method it is classified as Lit-BS and if a pair has multiple pieces of evidence, with at least one 
corresponding to a binary method then it is annotated as Lit-BM. The resulting number of PPIs 
in each category is shown in (Extended Data Fig. 9a). 
The interactions that make up the literature come from experiments that span a broad 
range of different sizes. It is possible that there could be a difference in average quality between 
experiments that report just a single or small number of PPIs and those that use high-
throughput techniques to identify large numbers of PPIs. In order to investigate this we divided 
the Lit-BM and Lit-BS into High-Throughput (HT) and Low-Throughput (LT) subsets, based on 
the size of the smallest experiment, that provided a piece of evidence for that pair using a binary 
experimental method. If 50 or more PPIs were reported in that experiment, it was classified as 
HT and otherwise was classified as LT. Random samples of these subsets were pairwise tested 
using Y2H (assay version 1) and MAPPIT (Extended Data Fig. 9b, c, Supplementary Table 24, 
25). We observed no significant difference between the validation rates of the HT and LT 
subsets and so we made the decision not to implement any cutoff in experiment size when 
defining the literature dataset.  
The main differences from the previous literature curated dataset Lit-BM-1310 are the 
databases used. Random samples of Lit-BM-17 pairs show similar recovery rates to random 
samples of Lit-BM-13 pairs in Y2H and MAPPIT (Extended Data Fig. 9d, e). PPIs from Lit-BM-
13 have been used as positive controls in experiments, PPIs from Lit-BM-17 (Supplementary 
Table 26) have been used in all computational analyses. 
 
Processing of co-complex interactome maps BioPlex, QUBIC, CoFrac 
BioPlex8 v2.0 data was downloaded from http://bioplex.hms.harvard.edu on August 1st, 2018, 
and protein IDs were mapped from UniProt to Ensembl gene IDs. QUBIC was downloaded from 
the supplementary table of the previous study9 and protein IDs were mapped from UniProt to 
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Ensembl gene IDs. CoFrac7 was processed by downloading the data from 
http://human.med.utoronto.ca on August 1st, 2018 and mapping from UniProt to Ensembl gene 
IDs. All interatome maps were then filtered to contain interactions only involving Ensembl gene 
IDs corresponding to protein-coding genes. 
 
Processing of previously generated binary interactome maps at CCSB 
To update the previous CCSB (the Center for Cancer Systems Biology) binary interactome 
maps and convert them into Ensembl gene ID pairs, for each map, we retrieved the original 
ORF based IDs stored in our database and mapped the ORF IDs to Ensembl gene IDs as 
described above. PPIs involving ORFs that remained unmapped or were discarded or mapped 
to non-protein-coding genes were removed. 
 
Analysis of HuRI PPIs linking proteins within versus between protein 
complexes 
 
CORUM22 complexes were downloaded from http://mips.helmholtz-muenchen.de on August 1st 
2018 and gene IDs were mapped from UniProt to Ensembl. Complexes with less than three 
subunits were removed as well as complexes that overlapped 90% or more with another 
complex (the smaller complex of both was removed). HuRI PPIs were filtered to remove 
homodimers and were restricted to those linking proteins annotated to be in at least one 
CORUM complex (restriction to common space between HuRI and CORUM). The fraction of 
these HuRI PPIs that link a pair of interacting proteins that were observed to be at least once 
part of the same CORUM complex was determined and these PPIs were further split into PPIs 
found in only one of the 9 HuRI screens versus having been found in at least 2 screens. The 
fractions plotted were 137/1042 and 232/775 for one screens and multiple screens, respectively. 
CORUM complex membership was used to identify all interactions between them from BioPlex8 
or HuRI. py2cytoscape111 was used to generate network models of each complex.  
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Functional enrichment analyses of HuRI and the Profile Similarity Network 
(PSN) of HuRI 
 
Construction of PSN and randomizations 
Jaccard similarity (number of shared interaction partners divided by union of interaction 
partners) was calculated for every pair of proteins of degree ≥ 2 in a given network. Only pairs 
of proteins that shared at least one interaction partner were considered in any further analysis 
using the PSN. Random PSNs were generated in the same way from degree-controlled 
randomized HuRI networks that generated using the degree_sequence() function in the Python 
igraph112 library v0.7.1. 
 
Calculation of pairwise sequence identity and correlation with Jaccard similarity 
To calculate the sequence identity between a pair of proteins in HuRI, we aligned the two 
corresponding ORF protein sequences using MUSCLE99 (v3.8.31) with default parameters. We 
then parsed the MUSCLE alignment file and calculated the sequence identity as the number of 
matched amino acid positions divided by the length of the alignment. To assess whether higher 
Jaccard similarity between two proteins in HuRI correlates with higher overall sequence 
similarity between the two proteins as an indication for similar interaction interfaces while 
controlling for degree biases, we computed for increasing sequence identity cutoffs the sum of 
Jaccard similarities of all edges in the PSN that link two proteins with a sequence identity of or 
above that cutoff. This sum was divided by the mean of the sums calculated in identical ways 
from 100 random PSNs to obtain a fold change that was plotted. The lower and upper bound of 
the 95% confidence interval of the fold change was computed by dividing the actual sum of the 
Jaccard similarities with the 97.5th and 2.5th percentile of the random distribution, respectively, 
and plotted as error bars. 
 
Retrieval and processing of resources for functional annotations 
Co-fitness relationships between human genes were kindly provided by Joshua Pan, calculated 
as a Pearson correlation coefficient between the effects of the separate knockout of two genes 
on the AVANA cancer cell line panel113 as described previously35. Gene IDs were mapped to 
Ensembl gene IDs and restricted to protein-coding genes. Co-expression data on the level of 
correlated expression between two genes was downloaded from the SEEK114 database on June 
13th 2018 and restricted to protein-coding genes. Pathway membership of proteins was 
obtained from Reactome, using a file mapping Ensembl gene IDs to lowest level pathways, 
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downloaded on August 1st 2018. Subcellular compartment membership of proteins was 
obtained from the Human Protein Atlas downloaded on August 1st 2018. Annotations of 
‘Uncertain’ reliability were not used. Protein complex membership of proteins was obtained from 
BioPlex8 2.0 supplementary table 7. Entrez gene IDs were mapped to Ensembl gene IDs and 
restricted to protein-coding genes. 
 
Calculation of significances for a network to link functionally related proteins 
The significance of a given network [HuRI, HuRI 2ev (HuRI with multiple evidences), or the PSN 
of HuRI] to link proteins that are co-expressed or that display similar growth defects on cell lines 
was determined by computing for increasing correlation cutoffs the sum of the edge weights 
(Jaccard similarities for PSN, edge weights = 1 for PPI networks) of all edges in the given 
network that link two proteins with a correlation value of at least that cutoff. This sum was 
divided by the mean of the sums obtained from randomized networks. the 95% confidence 
interval was computed as described above. A single correlation cutoff (Pearson correlation 
coefficient of 0.3 for growth defects and co-expression value of 0.86) was chosen for display 
based on the number of pairs of proteins that met this cutoff. However, consistent trends were 
observed across most cutoffs tested (Extended Data Fig. 4d, e). The significance and 
confidence interval of a given network to link proteins that localize to the same subcellular 
compartment, or work in the same pathway, or associate in the same protein complex was 
computed in identical ways with the exception that no titration was performed to calculate 
significances. 
 
Computation and visualization of functional modules 
We used the SAFE software28 (v1.5) to determine and visualize significant functional modules in 
various networks. The network layouts were generated with Cytoscape115 (v3.4.0) using the 
edge-weighted spring embedded layout. PSNs were drawn using a Jaccard similarity cutoff of 
≥0.1 and using the Jaccard similarity as edge weight for the layout algorithm. Gene Ontology116 
(GO) terms for each gene were extracted from FuncAssociate117 (v3 - GO updated on February 
2018). SAFE analysis was run with the default option except layoutAlgorithm = none (using 
layout generated by Cytoscape), neighborhoodRadius = 200, and neighborhoodRadiusType = 
absolute. 
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Network coverage of genes of interest and correlation with gene properties 
 
Acquisition and Processing of gene properties 
The number of publications for each gene was determined as the number of unique PubMed 
IDs associated with the gene, using the file gene2pubmed from NCBI downloaded on August 
1st 2018, after mapping NCBI gene IDs to Ensembl gene IDs, using the ID mapping file 
provided by NCBI, gene2ensembl, downloaded on August 1st 2018. Disease genes were 
defined as all genes with a disease annotation in OMIM118, using files generated on July 26th 
2018. Pharmacological targets were taken from the IUPHAR/BPS Guide to 
PHARMACOLOGY119 downloaded on July 26th 2018. Cancer genes were the Tier 1 genes of 
the Cancer Gene Census120. Genes with Single Nucleotide Polymorphism (SNP) from Genome-
Wide Association Study (GWAS) were selected using data from the GWAS Catalog121 v1.0.2 
from July 17th 2018. Genes were selected if there was a SNP associated with a trait with P < 5 
x 10-8, associated with the gene that belonged to a class that could affect the protein product. 
Transcription factors (TFs) were all known and likely TFs from The Human Transcription 
Factors122 v1.01 downloaded on July 26th 2018. Cell growth genes were derived from the 
AVANA CRISPR knockout screens113, using a file dated June 21st 2018 containing data for 436 
cell lines. Cell growth genes were selected as those with a median relative growth < -0.5 across 
the cell lines tested. We took the list of genes annotated with “embryonic lethality” from the MGI 
database (v6.13)34. Transcript expression levels of genes were retrieved from GTEx, and 
protein expression levels from HEK293T and HeLa cell lines from these studies9,123. Age 
information was adopted from Protein Historian36 (http://lighthouse.ucsf.edu/ProteinHistorian, 
downloaded on August 2nd 2018). Age time was computed based on OrthoMCL. LoF 
intolerance was adopted from ExAC database1 (release 0.3.1 / updated February 27th 2017). 
Summary and detailed information of gene properties is provided in Supplementary Table 27. 
 
Calculation and plotting of binned adjacency matrices 
The protein-coding genome is ranked by the number of publications of each gene. In the case 
where multiple genes have the same number of publications, the order was randomized. The 
genome was divided into equal-sized bins, dividing the symmetric genome-by-genome space 
into two-dimensional bins. 
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Processing of gene properties for network degree correlation analysis 
We calculated the correlation and the partial correlation between network degree of each 
network and protein properties within the set of proteins with at least one interaction in the 
corresponding network and with the value for the corresponding property, using Matlab (version 
2016a). To calculate the partial correlation based on expression, we used HEK293T proteomic 
data from the BioPlex123 v1.0 study, proteomics data from the HeLa cell line from the QUBIC 
study, GTEx tissue expression data and the number of publications from NCBI (method above) 
for the networks BioPlex, QUBIC, CoFrac and Lit-BM, respectively. 
 
Integrative analyses of HuRI with subcellular compartment data 
 
Calculation of protein coverage of networks by subcellular compartments 
The subcellular localization dataset was retrieved from Cell Atlas38 and processed as described 
above. Any compartments with less than 100 proteins were not considered in this analysis, and 
additional extracellular region and extracellular vesicle annotations from the GO database were 
included. Fisher’s exact test was used to test for an enrichment or depletion of the proteins of 
each network restricted to those that have at least one localization annotation. Odds ratios were 
provided in log scale and colored with gray for non-significant enrichment (P > 0.05). 
 
Calculation of trend between cellular compartment overlap and HuRI 
For pairs of subcellular compartments, A and B, both the odds ratio of proteins to be annotated 
in both A and B and the odds ratio of the density of PPIs between proteins annotated as being 
in A and not B and B and not A, were calculated. The density of PPIs is the number of PPIs 
within a set of proteins, divided by the number of pairwise combinations of those proteins. 
Haldane-Anscombe corrected odds ratios were used. The uncertainties on the log odds ratios 
were calculated using the standard error approximation. Orthogonal distance regression (ODR) 
was used to estimate the relationship between the two log odds ratios. ODR was chosen since 
the subcellular compartments have a large variation in their sizes and so widely varying 
uncertainties on both the x and y variables needed to be accounted for. The z-value of the 
regression slope was used as the test-statistic and compared to a null distribution generated by 
running the same regression analysis on 1,000 degree-preserved randomized networks. All 
possible pairs of compartments were used, with the exclusion of pairs of compartments whose 
annotations partially or fully excluded each other for technical reasons. The excluded pairs 
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were: Nucleoplasm/Nucleus, Nucleoplasm/Nucleoli, Nucleus/Nuclear Speckles, Nucleoli fibrillar 
center/Nucleoli, and Microtubule organizing center/Centrosome.  
 
Analysis of HuRI PPIs about extracellular vesicle function 
 
Acquisition and processing of extracellular vesicle (EV) proteomic data from the EVpedia 
database 
We used EVpedia database40,124,125 (version: April 30th 2018) to define vesicular proteins. In 
EVpedia, there are 487 studies for EV proteomics from human samples and an “Identification 
Count” for each protein, which is the number of EV proteomic studies with the corresponding 
protein detected. If a protein was found in more than 45 different studies (~10% of the studies), 
we defined it as a vesicular protein, resulting in 2,548 proteins in total (about top 10% among all 
the identified EV proteins). The Largest Connected Component (LCC) of this EV network, 
containing 525 proteins, was visualized with Cytoscape115 (v3.4.0). To test the significance of 
this EV protein network, we compared the number of PPIs between EV proteins in this network 
to the number of PPIs between EV proteins obtained in 1,000 degree-controlled randomized 
networks, deriving an empirical P < 0.001. 
 
Design and Transfection of gRNA and selection for KO cells 
We used gRNA shared in TKO database126. U373vIII cells were prepared at 70% confluency 
prior transfection. For each gene to be KO, a pool of plasmids carrying the gRNAs were 
transfected using JetPrime according to the manufacturer’s guidelines (Polyplus Transfection). 
The cells were submitted to Puromycin selection 36h after 48h of transfection. KO of SDCBP 
was confirmed by Western Blot127 with the rabbit anti-SDCBP antibody (ab133267 with lot 
number GR282684-7) purchased from Abcam (Cambridge). 
 
Comparative proteomics 
We performed the EV comparative proteomics as previously described127 with some 
modifications. The conditioned media (CM) was collected from cells grown for 72 h in culture 
media containing 10% EV-depleted FBS (generated by centrifugation at 150,000 g for 18 h at 
4ºC). CM was centrifuged at 400 g and then passed through 0.8 µm pore-size filter. The 
resulting filtrate was concentrated using Amicon Ultra-15 Centrifugal Filter Unit (EMD Millipore) 
with 100,000 nominal molecular weight limit (NMWL) molecular cutoff. The concentrate was 
mixed with 50% of iodixanol solution (Sigma) and processed for density gradient 
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ultracentrifugation at 200,000 g for 2 h. The EV-enriched fraction of iodixanol was collected (at 
the density of ∼1.10 g/mL) and particles were confirmed to carry CD81, an established 
exosome marker. The concentration of EV proteins was quantified using the BCA assay (Pierce 
Biotechnology). For concentration and size distribution of EVs, nanoparticle tracking analysis 
(NTA) was carried out with each collected iodixanol fraction using NanoSight NS500 instrument 
(NanoSight Ltd.). Three recordings of 30 s at 37 ºC were obtained and processed using NTA 
software (v3.0). 
The purified EV protein preparation (9 µg) was desalted with SDS-PAGE loaded onto the 
stacking gel followed by staining and destaining. The in-gel trypsin digestion was carried out 
under reducing conditions afforded by DiThioThreitol (DTT), and alkylation was achieved using 
iodoacetic acid. The lyophilized peptides were re-solubilized in 0.1% aqueous formic acid/2% 
acetonitrile, the peptides were loaded onto a Thermo Acclaim Pepmap (75 µm inner diameter 
with 2 cm length, C18, 3 µm particle size, 100 Å pore size; Thermo Fisher Scientific) pre-column 
and onto an Acclaim Pepmap Easyspray (75 µm inner diameter with 15 cm length, C18, 2 µm 
particle size, 100 Å pore size; Thermo Fisher Scientific) analytical column. Separation was 
achieved using a Dionex Ultimate 3000 uHPLC at 220 nL/min with a gradient of 2-35% organic 
solvents (0.1% formic acid in acetonitrile) over 3 h. Peptides were analyzed using an Orbitrap 
Fusion Tribrid mass spectrometer (Thermo Fisher Scientific) operating at 120,000 resolution 
(FWHM in MS1, 15,000 for MS/MS). All experiments were carried out in three biological 
replicates. The quantification of proteins was done by Maxquant program (v1.5.6.5) with default 
parameters of label-free quantification with UniProt database of human proteins (SwissProt 
release September 2016). To define the decreased proteins after knockout, P-value was 
calculated by fitting a Gaussian kernel density estimation (KDE) to the distribution of t-statistics 
obtained by randomly permuting the WT/KO labels for all proteins, as previously described128. 
Decreased proteins in EV after knockout were defined as the proteins with P < 0.05 and fold 
change < 0.66 (Fig. 4e). The enrichment of decreased proteins among SDCBP interactors were 
tested with empirical testing; among all the EV proteins from U373vIII, we randomly picked 6 
proteins 10,000 times and calculated the fraction of cases with ≥ 50% decrease proteins 
(Extended Data Fig. 5b). 
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605451doi: bioRxiv preprint first posted online Apr. 10, 2019; 
42 
Inference and analysis of tissue PPI networks from HuRI 
 
Calculation and assessment of tissue preferential expression 
A z-score related statistic published in Sonawane et al.44 was applied on the sample expression 
data of 35 tissues and testis to calculate a tissue preferential expression (TiP) value for every 
gene-tissue pair (Extended Data Fig. 10a and Supplementary Table 28). However, at a given 
TiP value cutoff, only those genes were considered preferentially expressed in a given tissue, if 
they also showed a level of expression > 5 in that tissue. A unique value of preferential 
expression for every gene was calculated by taking the maximum of all TiP values across the 35 
tissues (Extended Data Fig. 10a). As noted by others2,44, testis by far represents the tissue with 
the largest number of TiP genes increasingly dominating the overall set of TiP genes for 
increasing TiP value cutoffs (Extended Data Fig. 10b). The expression of many genes in testis 
has been hypothesized to be linked to DNA integrity control mechanisms during reproduction129 
suggesting that the majority of testis-specific genes are not related to testis-specific function. 
Therefore, testis was excluded from any analysis involving tissue-preferential expression in this 
study. The impact of that decision on the number of TiP genes defined for all other tissues was 
minimal, leading to a small gain in TiP genes and essentially no loss (Extended Data Fig. 10c, 
d). The number of TiP genes substantially decreases for increasing TiP value cutoffs (Extended 
Data Fig. 10a). At higher TiP value cutoffs, some tissues are left without any TiP gene. At a TiP 
value cutoff of 2, most TiP genes are not exclusively expressed. However, that fraction 
increases with higher TiP value cutoffs and plateaus at about 75% with a cutoff of 8 or 9 
(Extended Data Fig. 10e). Where applicable, analyses were performed without the application of 
a TiP value cutoff to define TiP genes, however, whenever a cutoff was necessary, a cutoff of 2 
(lenient but highly significant preferential expression), 3, and 8 were applied to test for 
dependencies of results on the level of preferential expression considered. 
 
Correlation analysis of network properties with tissue preferential expression 
Networks were processed as described above. A PPI was considered to exist in a tissue, if both 
proteins showed expression (at the transcript level, expression cutoff > 5) in the same sample 
for more than 50% of all samples available for that tissue. For the network property analyses, 
each PPI network was restricted to the PPIs being expressed in at least one tissue and to the 
largest connected component. The degree and betweenness function from the python igraph 
library112 (v0.7.1) were used to calculate the degree and betweenness of every protein in the 
network. Degree and betweenness were assessed for correlation with the max TiP value of 
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every protein using Spearman’s rank correlation in the python scipy library130 (v1.1.0). The 95% 
confidence interval of Spearman’s ρ was calculated using 1,000 bootstrap samples. 
 
Calculation of fraction of genome or network that is tissue-specific 
Networks were processed as described above and restricted to PPIs linking proteins expressed 
in the same tissue. Titrations were performed as described above, by the max TiP value of 
every gene. The fraction of the genome that is tissue-specific at a given max TiP value cutoff 
was calculated by dividing the number of TiP genes at the cutoff with the number of protein-
coding genes in GTEx. The fraction of proteins in a network that are tissue-specific were 
calculated by dividing the number of TiP proteins at a given max TiP value cutoff that are in the 
network with the total number of proteins in the filtered network. Error bars reflect standard error 
of proportion. 
 
Generation and visualization of TiP networks 
TiP networks were drawn for every tissue by taking all TiP proteins for a given tissue with a TiP 
value ≥ 2 and all their interaction partners in HuRI that are expressed in the same tissue. 
Networks were drawn with Cytoscape115 (v3.7.0) and manually adjusted for aesthetic purposes. 
The human body clipart was obtained from smart.servier.com. 
 
Calculation of closeness of TiP proteins in tissue PPI networks 
For every tissue the number of PPIs in HuRI between TiP proteins of that tissue was determined 
defining TiP proteins at a TiP value cutoff ≥ 2. This number was compared to the number of 
PPIs between TiP proteins in 1,000 degree-controlled randomized networks (generated using 
the degree_sequence function in the python igraph112 library) of the corresponding tissue PPI 
network of HuRI (all PPIs linking proteins expressed in this tissue). Tissues were excluded from 
the analysis, if less than two TiP proteins were in the tissue PPI network. The average shortest 
path between TiP proteins in a tissue PPI network was calculated by restricting the tissue PPI 
network to the Largest Connected Component (LCC), determining the shortest path of every TiP 
protein to the closest TiP protein and averaging those shortest paths, and comparing the 
average shortest path to those from 1,000 degree-controlled randomized tissue PPI networks. 
Tissue PPI networks with less than two TiP proteins in the LCC were excluded from the 
analysis. Tissues in which TiP proteins are significantly close to each other were determined by 
calculating the fraction of random networks with a number of TiP-TiP PPIs at least as high as in 
the actual tissue PPI network (or with an average shortest path at least as small or smaller) and 
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requiring that fraction to be ≤ 0.05 × 35 (one-sided empirical p-value corrected for multiple 
testing). 
 
Gene function prediction and experimental testing 
 
Analysis of annotation of TiP genes with tissue-specific GO terms 
Assignment of tissues to GO116 terms was done manually as described in detail elsewhere 
(Basha et al. in preparation). These GO term - tissue annotations were further matched to the 
35 tissues with transcriptome data from GTEx. GO Biological Process terms were downloaded 
from FuncAssociate117 on March 20th 2018 excluding annotations with evidence codes ND and 
IBA. For every tissue all genes with a TiP value ≥ 2 were selected and the fraction of those 
determined with at least one GO term annotation assigned to that tissue. 
 
Prediction of gene functions using guilt-by-association approach 
Finding a new protein annotation can be described as a link prediction problem between a node 
representing the function and the proteins. Initially, we connect the functional node to each of 
the proteins annotated with this function and obtain a link prediction score for each other gene in 
the network based on our recently developed link prediction method27. As the result, the indirect 
score of protein i is obtained as where aik is the connection weight between nodes i and k and 
kj is the degree of node j. Intuitively, the indirect score integrates the amount of network 
similarity of the candidate node to the known proteins involved in this function. 
We then compare the original network-based indirect score (s) to a random benchmark, 
obtained by randomizing the network several times in a degree-preserved way. Calculating the 
z-score z=(s-sR)/sR is the traditional way of such comparison, obtained by standardizing the 
original score with the expectation value (sR) and standard deviation (sR) of the score that 
would be expected by chance. Yet, the z-score is not free from degree biases and prefers low-
degree nodes with an extremely small sR. As described elsewhere in detail (manuscript in 
preparation), we propose to apply a related measure, called the effect size. The effect size s-
sR-αsR is obtained by comparing the original score with the reasonably expected value of the 
random benchmark, estimated as the mean value (sR) and α-times the standard deviation (sR). 
In practice, we use α=2, selecting the same candidates as a traditional z-score threshold of z ≥ 
2, but ordering them based on the amount of signal beyond random expectations to avoid a bias 
towards low-degree nodes. To generate the benchmark distribution for each gene, we perform 
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10,000 degree-preserved randomizations over the human interactome and score each gene in 
each of the random networks. 
Functional annotations of genes with GO Biological Process terms were obtained as 
described above and further restricted to annotations with the evidence codes EXP, IMP, TAS, 
HMP, HEP, IDA, IGI, NAS, HGI, IEP, IC, HDA to avoid circularity introduced from using inferred 
GO annotations based on PPI data to infer more GO annotations using PPI data again. 
 
Cell culture, transfection and cell death assay 
Cell death assay was performed as described previously131. HeLa cells (obtained from American 
Type Culture Collection) were maintained in DMEM supplemented with 10% FBS, 0.2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen) at 37°C and 5% CO2. 
Cells were plated onto 96-well imaging plates (BD Biosciences) and transient transfection was 
performed using Lipofectamine 3000 according to the manufacturer’s instructions (Invitrogen). 
After 24h in transfection reagent, the cells were imaged on a BD Pathway 855 Bioimager (BD 
Biosciences) with a UAPO/340 20X objective (0.75 NA; Olympus). After 1 hour of imaging, cells 
were treated with 100 ng/ml of recombinant human TRAIL Apo/2L (PeproTech). The 
fluorescence signal and the time of death of transfected cells were calculated using ImageJ 
(NIH) software. 
 To assess the significance of a correlation between levels of OTUD6A expression and 
time of death, a Pearson correlation coefficient was calculated and its significance assessed by 
comparison to the Pearson correlation coefficients of 100,000 shufflings of the cell death and 
fluorescence measurements. 
 
Generation of apoptosis candidate networks 
Networks around OTUD6A and C6ORF222 were drawn with Cytoscape115 (v3.7.0). All 
interaction partners of OTUD6A and C6ORF222 in HuRI were selected as well as indirect 
interaction partners, if they had a known apoptosis GO annotation (restricted to those used in 
the gene function prediction, see above), to visualize the network neighborhood used to obtain 
the apoptosis prediction for the two candidate genes. This reference network was filtered using 
transcript expression data from GTEx for colon_transverse (expression cutoff > 5) and transcript 
expression data from the BLUEPRINT project61,62 for major eosinophils (log2(TPM+1) > 0.3). 
The same expression data was used to adjust the size of the nodes in the network to reflect 
transcript expression levels.  
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Analyses of tissue-specificity of Mendelian diseases 
 
Quantification of tissue-specificity of Mendelian diseases and integration with tissue 
gene expression data 
Tissues affected in Mendelian diseases were manually curated as described in detail elsewhere 
(Basha et al. manuscript in preparation). Briefly, disease information was downloaded from the 
OMIM database118 and tissues were annotated to diseases within phenotypic series. Affected 
tissues were matched to the 35 tissue names from GTEx. If brain was an affected tissue, all 
three brain subregions for which transcriptome data from GTEx was available (see above for 
processing of GTEx data), were assigned to the corresponding disease. Other tissues, such as 
heart, were processed the same way. Annotated causal gene information from OMIM was 
mapped and restricted to the protein-coding gene space.  
The distribution for how many diseases affect how many tissues was calculated by 
restricting the list of annotated Mendelian diseases and tissues to those where causal genes 
showed to be expressed in at least one disease-associated tissue (GTEx tissue expression > 
5). Tissues were grouped into tissue types (e.g. the three brain subregions were grouped into 
brain) and tissue types were counted for each disease. Diseases with at most three tissue types 
where the disease manifests were considered tissue-specific diseases and used in all 
downstream analyses. 
The diseases were split into those where all causal genes are TiP genes, some causal 
genes are TiP genes and no causal gene is a TiP gene as follows. For a given disease, every 
causal gene was assessed for its expression (expression > 5) in at least one of the annotated 
affected tissues of the given disease and whether it is preferentially expressed or not in that 
tissue (TiP value ≥ 2). For each disease, only causal genes that were expressed in at least one 
affected tissue were considered. All these causal genes for a given disease were counted 
based on their preferential expression and diseases grouped accordingly. 
 
Test for significance of connectivity between causal proteins and TiP proteins in HuRI 
To test for the significance of causal proteins of tissue-specific Mendelian diseases to interact 
with preferentially expressed proteins of the corresponding disease-associated diseases 
(hereafter referred to as disease tissues) we only considered those diseases where not a single 
causal proteins was found to be preferentially expressed in any of the corresponding disease 
tissues. Cutoffs were used as described above. For a given tissue only those HuRI PPIs were 
considered that linked proteins both expressed in that tissue. For every tissue, all causal genes 
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are considered that are expressed in that tissue but that are not preferentially expressed in that 
tissue and that are causal to a disease that specifically manifests in that tissue and where the 
disease corresponds to the above mentioned criteria. No causal gene or interaction was 
counted twice for the analysis within each tissue. The number of PPIs between these causal 
proteins and TiP proteins for each tissue as well as the number of causal proteins with at least 
one PPI to a TiP protein was determined for each tissue and compared to the distribution of the 
same counts observed in 1,000 degree-controlled randomized networks that were generated 
with the degree_sequence function in the python igraph library.  
 
Experimental design of pairwise test in Y2H to test perturbation of PPIs between causal 
proteins and TiP proteins by disease mutations 
Causal proteins were selected as follows. Causal proteins from tissue-specific diseases were 
considered, if that causal protein was expressed in a given disease tissue and interacted with a 
TiP protein of that tissue where the causal protein itself was not preferentially expressed (cutoff 
as described above) and the interaction between the causal protein and TiP protein was found 
with the causal protein as DB fusion. For all assay versions in which a valid causal protein - TiP 
protein interaction was found, all interactions from these assay versions found with the 
corresponding causal protein as DB fusion were selected for pairwise test. Interactions involving 
a causal protein with 30 or more interaction partners for a given assay version were removed to 
control the size of the experiment. PRS v1 and RRS v1 pairs17 were tested along as positive 
and negative control. 
 
Cloning of disease mutations 
Within the causal genes described above, we cloned variants that were annotated as 
pathogenic or likely pathogenic in ClinVar71 (May 2015) and disease modifying in HGMD100 
(v2016). Since then, ongoing reannotation efforts by ClinVar have classified some of these 
pathogenic variants as benign, conflicting or variants of uncertain significance (VUS). We 
generated the disease mutants by implementing an advanced high-throughput site-directed 
mutagenesis pipeline68,132,133 with some modifications as described below. For each mutation, 
two “primary PCRs” were performed to generate gene fragments containing the mutation and a 
“stitch PCR” was performed to fuse the two fragments to obtain the mutated ORF. For the 
primary PCRs, two universal primers (E2E forward and E2E reverse) and two ORF-specific 
internal forwards and reverse primers were used. The two ORF-specific primers contained the 
desired nucleotide change. The gene fragments generated by the primary PCRs were fused 
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together by the stitch PCR using the universal primers to generate the mutated ORF. The final 
product was a full length ORF containing the mutation of interest. All the mutated ORFs were 
cloned into Gateway donor vector, pDONR223, by a BP reaction followed by bacterial 
transformation and selection by spectinomycin. Two single colonies were picked per 
transformant. The mutated ORF was sequence confirmed by M13 PCR followed by pooling and 
sequencing the PCR products on the Illumina platform. The reads were aligned to the reference 
ORFs using bowtie 2103 (v2.2.3) and samtools134 (v1.2). Only those colonies with the correct 
mutation, fully covered by the reads, and without other mutations were considered sequence-
confirmed. The confirmed colonies were rearrayed and assembled followed by LR reaction and 
bacterial transformation to transfer the mutated ORFs in pDEST-DB. The plasmids were purified 
and transformed into Y8930 yeast strain for the pairwise test. 
Primers used for the experiment: 
E2E forward: GGCAGACGTGCCTCACTACTACAACTTTGTACAAAAAAGTTGGC 
E2E reverse: CTGAGCTTGACGCATTGCTAACAACTTTGTACAAGAAAGTTGG 
M13-reverse: GTAACATCAGAGATTTTGAGACAC 
M13-forward: CCCAGTCACGACGTTGTAAAACG 
See Supplementary Table 29 for ORF-specific primers used in the mutagenesis.  
 
Pairwise test of disease mutations 
All sequence-confirmed pathogenic, likely pathogenic, and reclassified alleles for all selected 
causal genes (see above) were subject to pairwise test along with the wild-type allele paired 
with all interaction partners in the respective assay versions as described above. Before the 
pairwise test was performed, the yeast strains containing the mutated or wild-type ORFs were 
Sanger sequenced to confirm the presence or absence of the mutations. Considering that all the 
entry clones used in the experiments have been full-length sequence verified, we were less 
stringent to call that a clone is sequence confirmed. Specifically, for ORFs with mutations, if 
either forward or reverse sanger reads confirmed the identity of the ORF and the presence of 
the mutations and there was no contradictory between the two reads, the clone was considered 
as sequence confirmed. Wild-type ORFs required one of the sanger reads confirming the 
identity of the ORF and absence of any of the tested mutations, and no contradictory between 
reads. 
The pairwise test was performed in 96 well format. In all, 50 mutants in 17 genes/ORFs 
were subjected to pairwise test. The ORFs were inoculated in SC-Leu and SC-Trp media 
overnight and mated in YEPD media the following day. After incubation at 30ºC overnight, the 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605451doi: bioRxiv preprint first posted online Apr. 10, 2019; 
49 
mated yeasts were transferred into SC-Leu-Trp media to select for diploids. Next day, the 
diploid yeasts were spotted on SC-Leu-Trp-His+3AT, SC-Leu-His+3AT+CHX and SC-Leu-Trp 
media to control for mating success. In parallel, we made lysates of all SC-Leu-Trp plates to 
perform SWIM PCR as described in the primary screening section. 
 
Sequence confirmation of pairwise test positives and negatives 
SWIM PCR product was sequenced and the sequencing reads were analyzed as described 
above in the primary screening section. Due to the short read length of the Illumina sequencing 
and the design of SWIM-seq, absence or presence of a mutation on the ORF sequence could 
not always be confirmed. Therefore, for a given pair, as long as the identities returned from the 
pipeline matched the tested ORF and its partner, the pair was considered as sequence 
confirmed. Both positives and negatives were sequenced and only combinations of sequence 
confirmed pairs including both wild-type and mutated ORFs with same interacting partners were 
included in the final analysis. 
 
Processing of pairwise test data 
Each spot was scored with a growth score ranging from 0 to 4, 0 being no growth, 1 being one 
or two colonies, 2 being some colonies, 3 being lot’s of colonies, 4 being a big fat spot where no 
individual colonies can be distinguished. Pairs for which the SC-Leu-Trp spot was scored as 3 
or 4 and for which the CHX and the 3AT spot were valid (yeasts were spotted and no 
contamination or other experimental failure) were considered as successfully tested. 
Successfully tested pairs were further classified into auto-activators, if growth on CHX was >2 or 
growth on CHX was = 1 and less than 3 on 3AT, else negatives, if there was no growth (growth 
score = 0) on 3AT or positives if there was growth > 0 on 3AT and no growth on CHX or growth 
> 2 and growth = 1 on CHX. Pairs were scored blindly with respect to their identity. 
 
Analysis of PPI perturbation data 
Only pairs that were successfully tested, classified as positive or negative, for which the wild-
type allele was classified as positive with a growth score ≥ 2, and that were sequence-confirmed 
were considered for all further analysis. An interaction was considered perturbed by an allele, if 
the growth score of the wild-type pair was at least 2 growth scores above the growth score for 
that interaction with the respective allele. If an interaction involving an allele was tested in 
multiple assay versions (because the wild-type PPI has been found in those originally), then a 
final decision on that interaction for being perturbed or not was based on the results from the 
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assay version where the wild-type interaction reached the highest growth score (in case of ties, 
order of priority was given to assay version 1, 2, 6). A causal gene was included in the analyses, 
if first, there was at least one interaction with a TiP interaction partner that was positive with a 
growth score ≥ 2 as wild-type and that was successfully tested (as defined above) for at least 
one of the pathogenic alleles of that causal gene and second, if more than half of all interactions 
of a causal protein subjected to pairwise test were classified as positive with a growth score ≥ 2. 
Network visualizations were drawn with Cytoscape115 (v3.7.0).  
 
Prediction and experimental confirmation of functionally divergent splice 
isoforms 
 
Finding tissue-regulated splicing exon 
For tissue-regulated alternative splicing information, we used a dataset78 previously defined in 
49 tissues, which was kindly shared by members of the Blencowe lab, and is now publicly 
available via vastDB135. For each of the events, we mapped Ensembl exon accession with 
respect to their genome coordinate information. A tissue regulated exon was defined, if there is 
more than 25% difference between maximum Percent Spliced-In (PSI) and minimum PSI (ΔPSI 
> 25) as previously described78. 
 
Finding protein domain regulated by alternative splicing and defining hub protein with 
possible partial loss of protein-protein interactions 
Based on the tissue-regulated exons we defined, we computationally derived the spliced-out 
HuRI ORFs without the corresponding exon. After that, we translated it and mapped domains 
for HuRI ORFs and the spliced-out HuRI ORFs with InterProScan136 (v5.16-55.0) with Pfam137 
(v28.0). We restricted to domains that are previously known to mediate protein-protein 
interactions using information from 3did79 (based on UniProt version 201804). The domains that 
were missing in transcripts with spliced-out exons were defined as domains regulated by the 
alternative splicing. If a spliced-out HuRI ORF partially loses its PPI-mediating domains, we 
define that ORF as a possible candidate for partial PPI loss by tissue-regulated alternative 
splicing (Supplementary Table 18). 
 
Analysis of NCK2 isoform expression in brain samples 
We gained the exon-specific RPKM (Reads Per Kilobase Million) from the Allen Institute for 
Brain Science - BrainSpan Atlas of the Developing Human Brain138 (www.brainspan.org). To 
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estimate the fraction of exon A inclusion, we divided the RPKM of exon A by the average RPKM 
of exon C1 and C2, which are two adjacent exons of exon A (Supplementary Table 19). 
 
Pairwise test of interaction partners of NCK2 with short and long isoform 
We used the orientation and Y2H assay version of the interactions where the corresponding 
protein interactions were found in HuRI. The pairwise test of these interactions was done as 
previously described139. 
 
NCK2 function in Zebrafish 
An antisense morpholino oligonucleotide, as well as a 5 nt-mismatched control morpholino 
oligonucleotide (Gene Tools, Inc.), was designed to knockdown expression of zNCK2B 
(ortholog of human NCK2) via inhibiting the removal of intron 2. Zebrafish embryos at the 1-cell 
stage were microinjected with 5 ng of the antisense zNCK2B or control morpholinos, and 
inhibition of splicing in zNCK2B was confirmed via RT-PCR at 1 dpf (days post fertilization; 
forward exon 2: TACGGCACAACAAGACCAGG, exon3 reverse: 
TTGACTATGGCCGGAGTGTT, intron2 reverse: CGTGTGCGGTCAAATTTATGC). To rescue 
the zNCK2B knockdown, full length and short form zNCK2B and human NCK2 (hNCK2) 
messenger RNA was cloned into the multiple cloning site of pCS2+MT, and transcribed with the 
SP6 mMessage machine kit (ThermoFisher). Purified mRNA was microinjected into 1-cell stage 
zebrafish embryos either alone, or in combination with the above morpholinos at a concentration 
sufficient to yield 0.5 fmol RNA per embryo. zNCK2B knockdown and rescued embryos were 
assayed at 48 hpf (hours post fertilization) for midbrain GFP expression in the zebrafish 
enhancer trap line SAGFF(LF)223A, where GFP was inserted adjacent to lhx9140. Wild-type AB 
embryos were similarly injected with zNCK2B or control morpholino and mRNA, fixed at 48 hpf 
and assayed by whole mount in situ hybridization for lef1 expression as previously described141. 
The midbrain specific lef1 expression domain was imaged and quantified by measuring the 2-
dimensional area with Image-J; the experimental groups were then compared via t-test with 
MicroSoft Excel. 
Data availability 
The PPI data from this publication has been submitted to the IMEx 
(http://www.imexconsortium.org) consortium through IntAct106 and assigned the identifier IM-
25472. HuRI, Lit-BM, and all previously published human interactome maps from CCSB are 
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available at http://interactome.dfci.harvard.edu/huri/ for search and download. All HuRI-related 
networks generated and analyzed in this study are available at NDExbio.org142 
(https://tinyurl.com/networks-HuRI-paper). The raw and analyzed proteomic data were 
deposited in the PRIDE repository143 with the accession number PXD012321. 
Code availability 
Custom code used in this study has been made available as Supplementary Data 1 for the 
reviewers and will be made public on github.com upon acceptance. 
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